“The United States, South Africa, and the European Union will temporarily stop the rollout of the Johnson & Johnson COVID-19 vaccine, after reports of it causing blood clots.” [Source: bbc.com]
The problems with the Johnson & Johnson COVID-19 vaccine follow reports that the AstraZeneca vaccine has similarly been linked to blood clots, as well as a dangerous blood condition known as capillary leak syndrome.
As with the AstraZeneca vaccine, Johnson & Johnson’s COVID-19 vaccine is what is known as a viral vector-based vaccine. This type of vaccine uses a modified version of a different virus (the vector) to deliver instructions, in the form of genetic material, to the body’s cells.
Many aspects of the immune response generated by viral vector-based vaccines are still not understood, however. The technique carries a risk of affecting genes controlling cell growth if the vector is incorporated in a critical part of the host DNA code, which may result in serious consequences.
Other major safety concerns for these vaccines relate to the possibility of inducing antibody production against DNA resulting in autoimmune diseases, developing tolerance to the viral protein introduced via the DNA, as well as the negative health impact of novel molecular adjuvants.
To learn more about the potential health risks of COVID-19 vaccines, read this in-depth article by Dr. Aleksandra Niedzwiecki and Dr. Rath.